Furthermore, NSD1 depletion may enhance sensitivity to cisplatin-based chemotherapy, suggesting a potential avenue for improved outcomes in HNSCC patients [11,12]. This evidence concerns the gene NSD1 and head and neck squamous cell carcinoma.